

Pharmaceutical Management Agency

Update

New Zealand Pharmaceutical Schedule

Effective 1 June 2009

Cumulative for May and June 2009.

Section H cumulative for April, May and June 2009



Contents

Summary of PHARMAC decisions effective 1 June 2009.....	3
Understanding Tender transitions.....	4
Pilocarpine eye drops	6
Metoprolol succinate tablets	6
Hydrocortisone powder tender	7
Consultation on the draft revised Funding Application Guidelines (Version 2)	7
Diltiazem changes	7
Looking Forward	8
Sole Subsidised Supply products cumulative to June 2009	9
New Listings.....	19
Changes to Restrictions.....	21
Changes to Subsidy and Manufacturer’s Price.....	22
Changes to Description	25
Changes to Sole Subsidised Supply	25
Delisted Items	26
Items to be Delisted	27
Section H changes to Part I	29
Section H changes to Part II	30
Section H changes to Part IV	33
Index	34

Summary of PHARMAC decisions

EFFECTIVE 1 JUNE 2009

New listings (page 19)

- Metoprolol succinate (Metoprolol-AFT CR) tab 23.75 mg, 47.5 mg, 95 mg and 190 mg

Note – the endorsement requirement for full funding does not apply to the Metoprolol-AFT CR brand of metoprolol succinate long-acting tablets as they are listed fully subsidised

- Hydrocortisone (ABM) powder- Only in combination
- Acetylcysteine (Martindale Acetylcysteine) – inj 200 mg per ml, 10 ml
- Pamidronate disodium (Pamisol) Inj 9 mg per ml, 10 ml
- Glibenclamide tab 5 mg

Decreased subsidy (page 22)

- Diltiazem hydrochloride (Cardizem CD) cap 120 mg, 180 mg and 240 mg
- Ropinirole Hydrochloride (Requip) tab 0.25 mg, 1 mg, 2 mg and 5 mg
- Ropinirole Hydrochloride (Requip Starter pack) tab x 42, 0.5 mg x 42, and 1 mg x 21
- Ropinirole Hydrochloride (Requip Follow-on Pack) tab 0.25 mg x 42, 1 mg x 42, and 2 mg x 63
- Gemcitabine Hydrochloride (Baxter and Biomed) inj 1 mg for ECP
- Oestrogens Conjugated equine (Premarin) tab 300 μ g and 625 μ g
- Oestrogens with medroxyprogesterone (Premia 2.5 or 5 continuous) tab conjugated 625 μ g equine with 2.5 mg or 5 mg medroxyprogesterone acetate tab
- Calcium folinate (Calcium Folate Ebewe) inj

Increased subsidy (page 22)

- Benzathine benzylpenicillin (Bicillin LA) inj 1.2 mega units 2.3 ml

Understanding Tender transitions


When medicines are no longer under patent, other suppliers are able to sell 'generic' versions. This allows for competition, often between several suppliers. Tendering for medicines has been a very successful strategy.

The company gets sole subsidised supply of the medicine for a fixed term (usually three years), and this security gives the supplier a major incentive to offer us the best price. As well as saving public health money through lower prices, tenders also secure the supply of medicines through a contract.

PHARMAC has run a tender every year since 1997, when one product was tendered - paracetamol. Twelve years later, nearly half of all subsidised medicines (by volume) are purchased through the tender, and this has generated savings of more than \$300 million. These savings are re-invested by funding new medications or widening of access to current medications.

In a small market like New Zealand, the tender has also been an important mechanism for securing supply of small-volume but important medicines through a contract.

PHARMAC thinks carefully about which medicines to tender for, and an advisory committee of doctors and pharmacists



assess the bids on clinical and packaging grounds before the tender process is finalised.

At the end of each month PHARMAC advises suppliers, pharmacists and wholesalers of the upcoming Tender results to be implemented. This advice is also published on our website.

Sometimes there can be confusion about the transition times from one brand of medicine to another. When a new brand is to be awarded sole subsidised supply, there is a 6 months transition period. This is the time from notification to the time that the sole subsidised supply begins. There is some information below to help explain the transition timeframe and the formula PHARMAC uses when implementing a brand change as part of the tendering process.

The following example from the Tender results in the 31 March 2009 notification facsimile is used to explain the process:

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed – listing for tender winning brand at the tender subsidy will occur on **1 May 2009**, reference pricing of non-tender winning brand will occur on **1 July 2009** and Sole Subsidised Supply commences on **1 October 2009**.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current Subsidy	New tender subsidy	Sole supply brand (Supplier)	Brands affected by reference pricing and delisting
Terazosin hydrochloride*	Tab 2 mg; 500 tablets, bottle	\$1.48 (28 tablets)	\$23.30 (500 tablets)	Apo-Terazosin (Apotex)	Hytrin (Abbott)

*This product will become fully subsidised.

The brand that won the tender (i.e. Apo-Terazosin) is listed on the Pharmaceutical Schedule on 1 May 2009, which is one month after the date of notification. The existing brand (i.e. Hytrin) is reference priced (the same subsidy) to the tender winning brand two months after that (1 July 2009). Three months following reference pricing (1 October 2009),


the tender winning brand (Apo-Terazosin) becomes the sole subsidised brand and the other brand (Hytrin) will be delisted.

Below is a pictogram of timelines for the implementing of the terazosin hydrochloride 2 mg tablet tender process. It clearly shows the milestones for each of the processes.



Example

2009



For all changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H) pharmaceutical suppliers are required to notify PHARMAC and the Pharmacy Guild by 4 pm on the 12th of the month prior to the change. This notification confirms listing information, price and the product's pharmacode. More information and product notification forms can be downloaded from PHARMAC's website – www.pharmac.govt.nz/ suppliers.

Sometimes the listing dates can change from what was originally notified. At times we will delay listing a product for registration



purposes or until we are certain there is sufficient stock in the market. Any change will be reflected in future Schedule Updates and notification facsimiles.

Pilocarpine eye drops

Sigma Pharmaceuticals have advised that they are no longer going to supply pilocarpine eyedrops (Piloft);

The stock of each formulation will run out as follows:

Piloft 1% August 2009

Piloft 2% May/June 2009

Piloft 4% July 2009

Piloft 6% May/June 2009

PHARMAC staff have been actively seeking alternative supply for several months and will provide an update on any information when it becomes available



Metoprolol succinate tablets

AFT's brand of metoprolol succinate long-acting tablets (Metoprolol-AFT CR) will be listed on the Pharmaceutical

Schedule from 1 June 2009. It will be fully funded for all patients. The current endorsement criteria that applies to metoprolol succinate will not apply to Metoprolol-AFT CR however they will continue to apply to Betaloc CR.

Hydrocortisone powder tender

As a result of a tender agreement, ABM's brand of hydrocortisone powder will be listed on the Pharmaceutical Schedule from 1 June 2009 and will become the sole subsidised brand of hydrocortisone powder from 1 November 2009.

The change to sole supply will include reduced subsidies for m-Hydrocortisone from 1 August 2009, and delisting of this brand from 1 November 2009.

Consultation on the draft revised Funding Application Guidelines (Version 2)

PHARMAC is inviting submissions on a revised version of the Funding Application Guidelines. The Application Guidelines are intended for anyone wanting to make a funding Application.

The aims of this revision include:

- aligning the Guidelines with version 2 of the Prescription for Pharmacoeconomic Analysis (PFPA) (<http://www.pharmac.govt.nz/2007/06/19/PFPAFinal.pdf>);
- improving the transparency and understanding of the application process; and
- further ensuring that the Guidelines specify

all the information that PHARMAC requires in the application process.

The draft revised Funding Application Guidelines are available on the Consultation page of the PHARMAC website at <http://www.pharmac.govt.nz/consultation>, under the heading 'Draft version 2 of the Funding Application Guidelines. Closes 1 July 2009'.

We invite you to send a submission to PHARMAC regarding your views on the draft version 2 of the Funding Application Guidelines by way of written submission to guidelines@pharmac.govt.nz. The deadline for response is 1 July 2009.

Diltiazem changes

From 1 June, the Dilzem SR and LA brands of diltiazem hydrochloride will be delisted from the Pharmaceutical Schedule. If you have any patients that are still using these brands then they will need to be switched to the appropriate alternative. For further

information regarding the alternatives please refer to the February Pharmaceutical Schedule Update or the clinical advice on the PHARMAC website (under the notification section)

Looking Forward

This section is designed to alert both pharmacists and prescribers to possible future changes. It may assist pharmacists to manage stock levels and keep prescribers up-to-date with proposals to change the Pharmaceutical Schedule.

Possible decisions for implementation 1 July 2009

- Methylphenidate hydrochloride (Ritalin) tab immediate release 10 mg – new listing
- Methylphenidate hydrochloride (Ritalin SR) tab sustained release 20 mg – new listing
- Methylphenidate hydrochloride (Ritalin LA) cap modified release 20 mg, 30 mg and 40 mg – new listing

Note: Ritalin and Ritalin SR will be subject to the same Special Authority criteria as Rubifen and Rubifen SR (methylphenidate immediate release and sustained release), whereas Ritalin LA will be subject to the same Special Authority criteria as Concerta (methylphenidate extended release).

- Pioglitazone (Pizaccord) tab 15 mg, 30 mg and 45 mg – new listing
Note: amended Special Authority restriction applying to pioglitazone
- Azithromycin (Arrow-Azithromycin) tab 500 mg – amended listing and widening of access via Special Authority
- Multivitamins (Ketovite, Paediatric Seravit and Ketovite Liquid) -amendment of Special Authority criteria
- Dipyridamole – widening of access via Special Authority to include patients who have either have had an ischaemic stroke, are aspirin-intolerant, or where aspirin is contraindicated.
- Bupropion hydrochloride (Zyban) tab modified-release 150 mg – new listing
- Valaciclovir (Valtrex) tab 500 mg – new listing under Special Authority criteria
- Spacer device (Volumatic) 800 ml – new listing under WSO
- Bosentan (Tracleer) tab 62.5 mg and 125 mg – new listing under Special Authority criteria
- Iloprost (Ventavis) nebuliser soln 10 µg per ml, 2 ml – new listing under Special Authority criteria
- Sildenafil (Viagra) tab 50 mg and 100 mg – new listing under Special Authority criteria

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Acetazolamide	Tab 250 mg; 100 tab	Diamox	2011
Aciclovir	Tab dispersible 200 mg Tab dispersible 400 mg	Lovir Lovir	2009
Allopurinol	Tab 100 mg; 250 Tab 300 mg; 100	Apo-Allopurinol	2011
Alprazolam	Tab 250 µg Tab 500 µg Tab 1 mg	Arrow-Alprazolam Arrow-Alprazolam Arrow-Alprazolam	2010
Apomorphine hydrochloride	Inj 10 mg per ml, 1 ml	Mayne	2009
Amantadine hydrochloride	Cap 100 mg	Symmetrel	2011
Amlodipine	Tab 5 mg Tab 10 mg	Apo-Amlodipine	2011
Amoxicillin	Drops 100 mg per ml; 30 ml OP Inj 250 mg; 10 pack Inj 500 mg; 10 pack Inj 1 g; 10 pack Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Ospamox Ibiamox Apo-Amoxi Ranbaxy Amoxicillin Ranbaxy Amoxicillin	2011 2010 2009
Aqueous cream	Crn 500 g; pot	AFT	
Ascorbic acid	Tab 100 mg	Apo-Ascorbic Acid	2009
Aspirin	Tab dispersible 300 mg Tab 100 mg	Ethics Aspirin Ethics Aspirin EC	2010
Atenolol	Tab 50 mg & 100 mg	Loten	2009
Atropine sulphate	Eye drops 1%; 15 ml OP Inj 600 µg, 1 ml Inj 1200 µg, 1 ml	Atropt AstraZeneca AstraZeneca	2011 2009
Azithromycin	Tab 500 mg	Arrow-Azithromycin	2009
Beclomethasone dipropionate	Metered aqueous nasal spray 50 µg Metered aqueous nasal spray 100 µg	Alanase Alanase	2009
Benzylpenicillin sodium (Penicillin G)	Inj 1 mega u; 10 inj	Sandoz	2011
Betamethasone valerate	Scalp app 0.1%	Beta Scalp	2009
Bezafibrate	Tab 200 mg; 90 tab	Fibalip	2011
Bicalutamide	Tab 50 mg	Bicalox	2011
Bisacodyl	Tab 5 mg	Lax-Tab	2010
Brimonidine tartrate	Eye drops 0.2%	AFT	2011
Bupivacaine hydrochloride	Inj 0.5%, 4 ml Inj 0.5%, 8% glucose, 4 ml	Marcain Isobaric Marcain Heavy	2010
Calamine	Lotion BP Crn, aqueous, BP	ABM ABM	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Calcitonin	Inj 100 iu per ml, 1 ml; 5 inj	Miacalcic	2011
Calcitriol	Cap 0.25 µg & 0.5 µg	Calcitriol-AFT	2009
Calcium	Tab eff 1 g; 30 tab	Calsource	2011
Calcium folinate	Inj 50 mg	Calcium Folate Ebewe	2011
Captopril	Tab 12.5 mg, 25 mg & 50 mg	Apo-Captopril	2010
Cefaclor monohydrate	Cap 250 mg Grans for oral liq 125 mg per 5 ml	Ranbaxy Cefaclor Ranbaxy Cefaclor	2010
Cefazolin sodium	Inj 500 mg Inj 1 g	Hospira	2011
Cefuroxime sodium	Inj 750 mg & 1.5 g	Zinacef	2011
Cetomacrogol	Crn BP	PSM	2010
Cetirizine hydrochloride	Tab 10 mg Oral liq 1 mg per ml; 200 ml	Zetop Cetirizine-AFT	2011
Chloramphenicol	Eye drops 0.5% Eye oint 1%	Chlorsig Chlorsig	2009
Chlorhexidine gluconate	Soln 4% Handrub 1% with ethanol 70% Mouthwash 0.2%	Orion Orion Orion	2011 2009
Chlorthalidone	Tab 25 mg	Hygroton	2009
Ciprofloxacin	Tab 250 mg Tab 500 mg Tab 750 mg	Rex Medical	2011
Citalopram	Tab 20 mg; 84 pack	Arrow-Citalopram	2010
Clarithromycin	Tab 250 mg Grans for oral liq 125 mg per 5 ml	Klamycin Klacid	2010
Clobetasol propionate	Crn 0.05%	Dermol	2009
Clonazepam	Tab 500 µg; 100 tab Tab 2 mg; 100 tab	Paxam Paxam	2011
Clotrimazole	Vaginal crn 2%; 20 g OP Crn 1% Vaginal crn 1% with applicator(s)	Clomazol Clomazol Clomazol	2010
Codeine phosphate	Tab 15 mg, 30 mg & 60 mg	PSM	2010
Colchicine	Tab 500 µg	Colgout	2010
Colestipol hydrochloride	Sach 5 g	Colestid	2010
Colistin sulphomethate	Inj 150 mg	Colistin-Link	2010
Compound electrolytes	Powder for soln for oral use	Enerlyte	2010
Cyclizine hydrochloride	Tab 50 mg	Nausicalm	2009
Cyclophosphamide	Tab 50 mg	Cycloblastin	2010
Cyproterone acetate	Tab 50 mg	Siterone	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Dantrolene sodium	Cap 25 mg & 50 mg	Dantrium	2009
Desferrioxamine mesylate	Inj 500 mg	Mayne	2010
Desmopressin	Nasal spray 10 mcg per dose	Desmopressin-PH&T	2011
Dexamethasone sodium phosphate	Inj 4 mg per ml, 1 ml Inj 4 mg per ml, 2 ml	Mayne	2009
Dexamphetamine sulphate	Tab 5 mg	PSM	2010
Dextrose	Inj 50%, 10 ml	Biomed	2011
Dextrose with electrolytes	Oral soln with electrolytes	Pedialyte – Plain Pedialyte – Bubblegum Pedialyte – Fruit	2010
Diclofenac sodium	Eye drops 1 mg per ml Inj 25 mg per ml, 3 ml Suppos 12.5 mg Suppos 25 mg Suppos 50 mg Suppos 100 mg Tab EC 25 mg & 50 mg Tab long-acting 75 mg & 100 mg	Voltaren Ophtha Voltaren Voltaren Voltaren Voltaren Voltaren Apo-Diclo Apo-Diclo SR	2011 2009
Didanosine (DDI)	Cap 125 mg, 200 mg, 250 mg & 400 mg	Videx EC	2009
Diltiazem hydrochloride	Tab 30 mg; 100 Tab 60 mg; 100 Cap long-acting 120 mg; 30 Cap long-acting 180 mg; 30 Cap long-acting 240 mg; 30	Dilzem Cardizem CD	2011
Dipyridamole	Tab long-acting 150 mg	Pytazen SR	2011
Doxazosin mesylate	Tab 2 mg & 4 mg	Apo-Doxazosin	2010
Emulsifying ointment	Oint BP	AFT	2011
Enalapril	Tab 5 mg, 10 mg & 20 mg	m-Enalapril	2009
Ergometrine maleate	Inj 500 µg per ml, 1 ml	Mayne	2009
Ergotamine tartrate with caffeine	Tab 1 mg with caffeine 100 mg	Cafergot	2009
Erythromycin ethyl succinate	Grans for oral liq 200 mg per 5 ml; 100 ml Grans for oral liq 400 mg per 5 ml; 100 ml	E-Mycin E-Mycin	2011
Ethinylestradiol	Tab 10 µg	New Zealand Medical and Scientific	2009
Ethinylestradiol with norethisterone	Tab 35 µg with norethisterone 500 µg Tab 35 µg with norethisterone 1 mg Tab 35 µg with norethisterone 1 mg and 7 inert tab	Brevinor 21 Brevinor 1/21 Brevinor 1/28	2010
Etoposide	Cap 50 mg & 100 mg	Vepesid	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Ferrous sulphate	Oral liq 150 mg per 5 ml	Ferodan	2010
Finasteride	Tab 5 mg; 30 tab	Fintral	2011
Flucloxacillin	Inj 250 mg; 10 pack Inj 500 mg; 10 pack Inj 1 g; 10 pack	Flucloxin	2011
Flucloxacillin sodium	Cap 250 mg & 500 mg Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml	Staphlex AFT AFT	2009
Fluconazole	Cap 50 mg Cap 150 mg Cap 200 mg	Pacific Pacific Pacific	2011
Fludarabine phosphate	Inj 50 mg Tab 10 mg	Fludara Fludara	2011
Fluocortolone caproate with fluocortolone pivalate and cinchocaine	Oint 950 µg, with fluocortolone pivalate 920 µg, and cinchocaine hydrochloride 5 mg per g Suppos 630 µg, with fluocortolone pivalate 610 µg, and cinchocaine hydrochloride 1 mg	Ultraproct Ultraproct	2010
Fluorometholone	Eye drops 0.1%	Flucon	2009
Fluoxetine hydrochloride	Cap 20 mg Tab disp 20 mg, scored	Fluox Fluox	2010
Folic Acid	Tab 0.8 mg & 5 mg	Apo-Folic Acid	2009
Fusidic acid	Crn 2% & Oint 2%	Foban	2010
Gentamicin sulphate	Inj 40 mg per ml, 2 ml	Pfizer	2009
Gliclazide	Tab 80 mg	Apo-Gliclazide	2011
Glipizide	Tab 5 mg	Minidiab	2011
Glyceril trinitrate	Tab 600 µg Oral pump spray 400 µg per dose TDDS 5 mg TDDS 10 mg	Lycinate Nitrolingual pumpspray Nitroderm TTS 5 Nitroderm TTS 10	2011
Haloperidol	Oral liq 2 mg per ml Tab 500 µg, 1.5 mg & 5 mg Inj 5 mg per ml, 1 ml	Serenace Serenace Serenace	2010 2009
Heparinised saline	Inj 10 iu per ml, 5 ml	AstraZeneca	2009
Hydrocortisone	Crn 1% Tab 5 mg & 20 mg	PSM Douglas	2011 2009
Hydrocortisone acetate	Rectal foam 10%, CFC-Free	Colifoam	2009
Hydrocortisone butyrate	Scalp lotn 0.1%	Locoid	2010
Hydrocortisone with wool fat and mineral oil	Lotn 1% with wool fat hydrous 3% and mineral oil	DP Lotn HC	2011
Hypromellose	Eye drops 0.5%	Methopt	2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Hysocine N-butylbromide	Inj 20 mg, 1 ml Tab 20 mg	Buscopan Gastrosoothe	2011
Ibuprofen	Oral liq 100 mg per 5 ml, 200 ml	Fenpaed	2010
Imipramine hydrochloride	Tab 10 mg & 25 mg	Tofranil	2009
Indapamide	Tab 2.5 mg	Napamide	2009
Ipratropium bromide	Aqueous nasal spray, 0.03% Nebuliser soln, 250 µg per ml, 1 ml Nebuliser soln, 250 µg per ml, 2 ml	Apo-Ipravent Ipratropium Steri-Neb Ipratropium Steri-Neb	2010
Iron polymaltose	Inj 50 mg per ml, 2 ml	Ferrum H	2011
Isosorbide mononitrate	Tab long-acting 60 mg	Duride	2009
Isotretinoin	Cap 10 mg Cap 20 mg	Isotane 10 Isotane 20	2009
Itraconazole	Cap 100 mg	Sporanox	2010
Ketoconazole	Shampoo 2%, 100 ml OP	Sebizole	2011
Lactulose	Oral liq 10 g per 15 ml	Duphalac	2010
Levobunolol	Eye drops 0.25% & 0.5%	Betagan	2010
Levodopa with benserazide	Cap 50 mg with benserazide 12.5 mg Tab dispersible 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg Cap 200 mg with benserazide 50 mg	Madopar 62.5 Madopar Dispersible Madopar 125 Madopar HBS Madopar 250	2009
Lignocaine hydrochloride	Inj 0.5%, 5 ml Inj 1%, 5 ml Inj 1%, 20 ml	Xylocaine Xylocaine Xylocaine	2010
Lignocaine with prilocaine	Crn 2.5% with prilocaine 2.5%; 30 g OP Crn 2.5% with prilocaine 2.5%; 5 g	EMLA EMLA	2010
Lisinopril	Tab 5 mg, 10 mg & 20 mg	Arrow-Lisinopril	2009
Loperamide hydrochloride	Tab 2 mg	Nodia	2010
Loratadine	Tab 10 mg Oral liq 1 mg per ml	Loraclear Hayfever Relief Lorapaed	2010
Lorazepam	Tab 1 mg & 2.5 mg	Ativan	2009
Magnesium sulphate	Inj 49.3%	Mayne	2009
Malathion	Liq 0.5%	Derbac M	2010
Maldison	Shampoo 1%	A-Lices	2010
Maprotiline hydrochloride	Tab 25 mg & 75 mg	Ludiomil	2009
Mask for Spacer Device	Device	Foremount Child's Silicone Mask	2011

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Mebeverine hydrochloride	Tab 135 mg; 90 tab	Colofac	2011
Medroxyprogesterone acetate	Tab 2.5 mg, 5 mg, 10 mg, 100 mg & 200 mg	Provera	2010
Mesalazine	Enema 1 g per 100 ml	Pentasa	2009
Metformin hydrochloride	Tab 500 mg & 850 mg	Arrow-Metformin	2009
Methadone hydrochloride	Tab 5 mg Powder 1 g	Methatabs AFT	2010 2009
Methotrexate	Inj 100 mg per ml, 10 ml Inj 100 mg per ml, 50 ml Tab 2.5 mg & 10 mg	Methotrexate Ebewe Methotrexate Ebewe Methoblastin	2011 2009
Methyl dopa	Tab 125 mg; 100 tab Tab 250 mg; 100 tab Tab 500 mg; 100 tab	Prodopa Prodopa Prodopa	2011
Methylphenidate hydrochloride	Tab long-acting 20 mg Tab 5 mg & 20 mg Tab 10 mg	Rubifen SR Rubifen Rubifen	2009
Methylprednisolone	Tab 4 mg & 100 mg	Medrol	2009
Methylprednisolone aceponate	Crn 0.1% and oint 0.1%	Advantan	2009
Methylprednisolone acetate	Inj 40 mg per ml, 1 ml	Depo-Medrol	2011
Methylprednisolone acetate with lignocaine	Inj 40 mg per ml with lignocaine 1 ml	Depo-Medrol with Lidocaine	2011
Methylprednisolone sodium succinate	Inj 40 mg per ml, 1 ml Inj 62.5 mg per ml, 1 ml Inj 500 mg & 1 g	Solu-Medrol Solu-Medrol Solu-Medrol	2009
Metoclopramide hydrochloride	Inj 5 mg per ml, 2 ml	Pfizer	2011
Metoprolol tartrate	Tab long-acting 200 mg	Slow-Lopresor	2009
Metyrapone	Cap 250 mg	Metopirone	2009
Miconazole nitrate	Crn 2%	Multichem	2011
Midodrine	Tab 2.5 mg & 5 mg	Gutron	2009
Misoprostol	Tab 200 µg	Cytotec	2009
Moclobemide	Tab 150 mg & 300 mg	Apo-Moclobemide	2009
Morphine hydrochloride	Oral liq 1 mg per ml Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	RA-Morph RA-Morph RA-Morph RA-Morph	2009

**Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.*

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Morphine sulphate	Inj 10 mg per ml, 1 ml	Mayne	2011
	Inj 30 mg per ml, 1 ml	Mayne	2009
	Inj 5 mg per ml, 1 ml	Mayne	
	Inj 15 mg per ml, 1 ml	Mayne	
	Cap long-acting 10 mg, 30 mg, 60 mg, 100 mg & 200 mg	m-Eslon	
	Tab immediate release 10 mg & 20 mg	Sevredol	
Morphine tartrate	Inj 80 mg per ml, 1.5 ml & 5 ml	Mayne	2009
Nadolol	Tab 40 mg & 80 mg	Apo-Nadolol	2010
Naltrexone hydrochloride	Tab 50 mg	ReVia	2010
Naproxen	Tab 250 mg	Noflam 250	2009
	Tab 500 mg	Noflam 500	
Naproxen sodium	Tab 275 mg	Sonafnam	2010
Neostigmine	Inj 2.5 mg per ml, 1 ml	AstraZeneca	2010
Nevirapine	Oral suspension 10 mg per ml	Viramune Suspension	2009
Nicotine	Patch 7 mg, 14 mg and 21 mg	Habitrol	2010
	Lozenge 1 mg and 2 mg	Habitrol	
	Gum 2 mg (Fruit)	Habitrol	
	Gum 2 mg (Mint)	Habitrol	
	Gum 4 mg (Fruit)	Habitrol	
	Gum 4 mg (Mint)	Habitrol	
Nicotinic acid	Tab 50 mg & 500 mg	Apo-Nicotinic Acid	2009
Nifedipine	Tab long-acting 20 mg	Nyefax Retard	2009
Norethisterone	Tab 5 mg	Primolut N	2011
	Tab 350 µg	Noriday 28	2009
Nortriptyline hydrochloride	Tab 10 mg; 100 tab	Norpress	2011
	Tab 25 mg; 250 tab	Norpress	
Nystatin	Oral liq 100,000 u per ml, 24 ml OP	Nilstat	2011
	Cap 500,000 u	Nilstat	2010
	Tab 500,000 u	Nilstat	2009
	Vaginal crm 100,000 u per 5 g with applicators	Nilstat	
Omeprazole	Cap 10 mg; 28 and 30	Dr Reddy's Omeprazole	2011
	Cap 20 mg; 28 and 30		
	Cap 40 mg; 28 and 30		
	Inj 40 mg; 5		
Ondansetron	Tab 4 mg & 8 mg	Zofran	2010
	Tab disp 4 mg & 8 mg	Zofran Zydis	
Oxybutynin	Tab 5 mg	Apo-Oxybutynin	2010
	Oral liq 5 mg per 5 ml	Apo-Oxybutynin	
Oxycodone hydrochloride	Inj 10 mg per ml, 1 ml and 2 ml	OxyNorm	2010
	Oral liq 5 mg per 5 ml	OxyNorm	

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Oxytocin	Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml	Syntocinon Syntocinon Syntometrine	2009
Pamidronate disodium	Inj 3 mg per ml, 5 ml Inj 3 mg per ml, 10 ml Inj 6 mg per ml, 10 ml	Pamisol Pamisol Pamisol	2011
Pantoprazole	Inj 40 mg; 1 inj Tab 20 mg Tab 40 mg	Pantocid IV Dr Reddy's Pantoprazole Dr Reddy's Pantoprazole	2010
Paracetamol	Tab 500 mg; 1,000 Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml	Pharmacare Paracetamol Paracare Junior Paracare Double Strength	2011
Paraffin liquid with soft white paraffin	Eye oint with soft white paraffin	Lacri-Lube	2010
Paroxetine hydrochloride	Tab 20 mg	Loxamine	2010
Peak Flow Meter	Low range	Breath-Alert	2011
Pergolide	Tab 0.25 mg Tab 1 mg	Permax Permax	2011
Perhexiline maleate	Tab 100 mg	Pexsig	2009
Phenoxymethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml Grans for oral liq 250 mg per 5 ml Cap potassium salt 250 mg Cap potassium salt 500 mg	AFT AFT Cilicaine VK Cilicaine VK	2010
Phenylephrine hydrochloride	Eye drops 0.12%	Prefrin	2010
Poloxamer	Oral drops 10%, 30 ml OP	Coloxyl	2011
Polyvinyl alcohol	Eye drops 1.4% Eye drops 3%	Vistil Vistil Forte	2011
Potassium chloride	Tab long-acting 600 mg	Span-K	2009
Prazosin hydrochloride	Tab 1 mg, 2 mg & 5 mg	Apo-Prazo	2010
Prednisone	Tab 1 mg; 500 tab Tab 2.5 mg; 500 tab Tab 5 mg; 500 tab Tab 20 mg; 500 tab	Apo-Prednisone Apo-Prednisone Apo-Prednisone Apo-Prednisone	2011
Pregnancy tests - HCG urine	Cassette	MDS Quick Card	2009
Procaine penicillin	Inj 1.5 mega u; 5 inj	Cilicaine	2011
Promethazine	Tab 10 mg Tab 25 mg	Allersoothe	2011
Pyridoxine hydrochloride	Tab 50 mg	Apo-Pyridoxine	2009

**Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.*

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Quinapril	Tab 5 mg; 10 mg & 20 mg	Accupril	2011
Quinapril with hydrochlorothiazide	Tab 10 mg with hydrochlorothiazide 12.5 mg	Accuretic 10	2011
	Tab 20 mg with hydrochlorothiazide 12.5 mg	Accuretic 20	
Quinine sulphate	Tab 200 mg	Q 200	2009
	Tab 300 mg	Q 300	
Ranitidine hydrochloride	Oral liq 150 mg per 10 ml	Peptisoothe	2010
Rifabutin	Cap 150 mg	Mycobutin	2010
Roxithromycin	Tab 150 mg & 300 mg	Arrow-Roxithromycin	2009
Salbutamol	Nebuliser soln 1 mg per ml, 2.5 ml	Asthalin	2009
	Nebuliser soln 2 mg per ml, 2.5 ml	Asthalin	
	Oral liq 2 mg per 5 ml	Salapin	2010
Salbutamol with ipratropium bromide	Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg	Duolin	2009
Selegiline hydrochloride	Tab 5 mg	Apo-Selegiline	2009
Sodium chloride	Inj 0.9%, 5 ml & 10 ml	AstraZeneca	2009
Sodium citro-tartrate	Grans eff 4 g sachets	Ural	2010
Sodium cromoglycate	Nasal spray 4%	Rex	2009
Spacer Device	230 ml	Space Chamber	2011
Sulphasalazine	Tab 500 mg	Salazopyrin	2009
	Tab EC 500 mg	Salazopyrin EN	
Syrup (pharmaceutical grade)	Liq	Midwest	2010
Tar with triethanolamine lauryl sulphate and fluorescein sodium	Soln 2.3%; 500 ml and 1,000 ml	Pinetarsol	2011
Temazepam	Tab 10 mg; 25 tab	Normison	2011
Terbinafine	Tab 250 mg	Apo-Terbinafine	2011
Testosterone cypionate	Inj long-acting 100 mg per ml, 10 ml	Depo-Testosterone	2011
Tetracosactrin	Inj 250 mcg	Synacthen	2011
	Inj 1 mg per ml, 1 ml	Synacthen Depot	
Timolol maleate	Eye drops 0.25%	Apo-Timop	2011
	Eye drops 0.5%	Apo-Timop	2009
	Tab 10 mg	Apo-Timol	
Thiamine hydrochloride	Tab 50 mg	Apo-Thiamine	2009
Triamcinolone acetonide	Crn 0.02%; 100 g OP	Aristocort	2011
	Oint 0.02%; 100 g OP	Aristocort	
	Inj 40 mg per ml, 1 ml; 5 inj 0.1% in Dental Paste USP	Kenacort-A40	2011
		Oracort	
Triamcinolone acetonide with gramicidin, neomycin and nystatin	Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	Kenacomb	2009

*Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.

Sole Subsidised Supply Products – cumulative to June 2009

Generic Name	Presentation	Brand Name	Expiry Date*
Trimethoprim	Tab 300 mg; 50 tab	TMP	2011
Ursodeoxycholic acid	Cap 300 mg	Actigall	2011
Vancomycin hydrochloride	Inj 50 mg per ml, 10 ml; 1 inj	Pacific	2011
Vincristine sulphate	Inj 1 mg per ml, 1 ml Inj 1 mg per ml, 2 ml	Mayne Mayne	2009
Vitamins	Tab (BPC cap strength)	Healtheries	2009
Vitamin B complex	Tab, strong, BPC	Apo-B-Complex	2009
Water	Purified for injection 20 ml	Multichem	2009
Zinc and castor oil	Ointment BP	PSM	2011
Zinc sulphate	Cap 220 mg; 100 cap	Zincaps	2011
Zopiclone	Tab 7.5 mg	Apo-Zopiclone	2011

June changes in bold type.

**Expiry date of the Sole Subsidised Supply period is 30 June of the year indicated.*

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings

Effective 1 June 2009

30	GLIBENCLAMIDE * Tab 5 mg	5.00	100	✓ Daonil
53	METOPROLOL SUCCINATE * Tab long-acting 23.75 mg	2.73	30	✓ Metoprolol-AFT CR
	* Tab long-acting 47.5 mg	3.41	30	✓ Metoprolol-AFT CR
	* Tab long-acting 95 mg	5.88	30	✓ Metoprolol-AFT CR
	* Tab long-acting 190 mg	10.63	30	✓ Metoprolol-AFT CR
Note – the endorsement requirement for full funding does not apply to the Metoprolol-AFT CR brand of metoprolol succinate long-acting tablets as they are listed fully subsidised.				
61	HYDROCORTISONE * Powder – Only in combination	33.00	25 g	✓ ABM
104	PAMIDRONATE DISODIUM Inj 9 mg per ml, 10 ml	112.50	1	✓ Pamisol
163	ACETYLCYSTEINE – Hospital pharmacy [HP1]-Specialist Inj 200 mg per ml, 10 ml	137.06 (219.75)	10	Martindale Acetylcysteine

Effective 1 May 2009

46	ATORVASTATIN – Additional subsidy by Special Authority see SA0788 below – Retail pharmacy See prescribing guideline on the preceding page * Tab 80 mg	16.28 (110.50)	30	Lipitor
49	TERAZOSIN HYDROCHLORIDE * Tab 1 mg	2.50	28	✓ Apo-Terazosin
	* Tab 2 mg	23.30	500	✓ Apo-Terazosin
	* Tab 5 mg	29.00	500	✓ Apo-Terazosin
87	CO-TRIMOXAZOLE * Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO	2.15	100 ml	✓ Deprim
110	NORTRIPTYLINE HYDROCHLORIDE Tab 25 mg	14.44	180	✓ Norpress
138	PACLITAXEL – PCT only – Specialist Inj 30 mg	189.75	5	✓ Paclitaxel Ebewe
172	PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3] Liquid (strawberry)	1.60	200 ml OP	✓ NutriDrink
	Liquid (vanilla).....	1.60	200 ml OP	✓ NutriDrink

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

New Listings - effective 1 May 2009 (continued)

172	PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3]				
	Liquid (strawberry)	1.60	200 ml OP	✓ NutriniDrink Multifibre	
	Liquid (chocolate)	1.60	200 ml OP	✓ NutriniDrink Multifibre	
	Liquid (vanilla)	1.60	200 ml OP	✓ NutriniDrink Multifibre	

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$

Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Restrictions

Effective 1 May 2009

55	FRUSEMIDE FUROSEMIDE			
	* Tab 40 mg – Up to 30 tab available on a PSO	10.75	1,000	✓ Diurin 40
	* Tab 500 mg	12.00	100	✓ Diurin 500
	*‡ Oral liq 10 mg per ml.....	10.66	30 ml OP	✓ Lasix
	* Infusion.....	481.40	5	✓ Lasix
	* Inj 10 mg per ml, 2 ml – Up to 5 inj available on a PSO	29.50	50	✓ Mayne
59	GICLOPIROXOLAMINE CICLOPIROXOLAMINE			
	a) Only on a prescription			
	b) not in combination			
	Nail soln 8%	19.85	3.5 ml OP	✓ Batrafen

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price

Effective 1 June 2009

54	DILTIAZEM HYDROCHLORIDE (↓ subsidy and price)			
	* Cap 120 mg	4.34	30	✓Cardizem CD
	* Cap 180 mg	6.50	30	✓Cardizem CD
	* Cap 240 mg	8.67	30	✓Cardizem CD
77	OESTROGENS – See prescribing guideline on the preceding page (↑ price)			
	* Conjugated, equine tab 300 µg	3.01	28	
		(11.48)		Premarin
	* Conjugated, equine tab 625 µg	4.12	28	
		(11.48)		Premarin
78	OESTROGENS WITH MEDROXYPROGESTERONE – See prescribing guideline on page 76 (↑ price)			
	* Tab Conjugated 625 µg conjugated equine with 2.5 mg medroxyprogesterone acetate tab (28)	5.40	28 OP	
		(22.96)		Premia 2.5 Continuous
	* Tab Conjugated 625 µg conjugated equine with 5 mg medroxyprogesterone acetate tab (28)	5.40	28 OP	
		(22.96)		Premia 5 Continuous
86	BENZATHINE BENZYL PENICILLIN (↑ price and subsidy)			
	Inj 1.2 mega µ per 2 ml – Up to 5 inj available on a PSO	315.00	10	✓Bicillin LA
118	ROPINIROLE HYDROCHLORIDE (↓ subsidy)			
	▲ Tab 0.25 mg	19.75	210	
		(31.50)		Requip
	▲ Tab 0.25 mg x 42, 0.5 mg x 42, and 1 mg x 21	21.92	105 OP	
		(35.70)		Requip Starter Pack
	▲ Tab 0.25 mg x 42, 1 mg x 42, and 2 mg x 63	73.60	147 OP	
		(122.11)		Requip Follow-on Pack
	▲ Tab 1 mg	40.32	84	
		(67.20)		Requip
	▲ Tab 2 mg	60.72	84	
		(101.21)		Requip
	▲ Tab 5 mg	90.00	84	
		(150.00)		Requip
132	CALCIUM FOLINATE – PCT – Hospital pharmacy [HP3]-Specialist (↓ price)			
	Inj 100 mg – PCT only – Specialist	9.75	1	✓Calcium Folate Ebewe
	Inj 300 mg – PCT only – Specialist	30.00	1	✓Calcium Folate Ebewe
	Inj 1 g – PCT only – Specialist	100.00	1	✓Calcium Folate Ebewe
133	GEMCITABINE HYDROCHLORIDE (↓ subsidy and price)			
	Inj 1 mg for ECP	0.26	1 mg	✓Baxter ✓Biomed

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Changes to Subsidy and Manufacturer's Price - effective 1 May 2009

25	CALCIUM CARBONATE WITH AMINOACETIC ACID * Tab 420 mg with aminoacetic acid 180 mg - Higher subsidy of \$6.30 per 100 with Endorsement.....	3.00 (6.30)	100		Titralac
	Additional subsidy by endorsement is available for pregnant women. The prescription must be endorsed accordingly				
30	ACARBOSE (↓ subsidy and price) – Special Authority see SA0925 below – Retail pharmacy * Tab 50 mg	16.50	90	✓	Glucobay
	* Tab 100 mg	26.70	90	✓	Glucobay
31	COPPER (↑ price) * Tab Diagnostic – Not on a BSO.....	5.02 (31.80)	36 OP		Clinitest
31	GLUCOSE OXIDASE (↑ price) Urine diagnostic test with peroxidase – Not on a BSO.....	4.13 (8.65)	50 strip OP		Clinistix
		4.11 (6.26)			Diastix
32	GLUCOSE OXIDASE (↑ price) Urine diagnostic test with peroxidase, potassium iodide, sodium nitroprusside and aminoacetic acid – Not on a BSO.....	4.53 (14.87)	50 strip OP		Keto-Diastix
32	SODIUM NITROPRUSSIDE (↑ price) * Urine diagnostic strip, buffered – Not on a BSO.....	3.40 (10.94)	50 strip OP		Ketostix
47	SIMVASTATIN (↓ subsidy)– See prescribing guidelines on page 45 * Tab 10 mg	0.68 (11.37)	30	✓	SimvaRex Lipex
	* Tab 20 mg	1.00 (11.67)	30	✓	SimvaRex Lipex
	* Tab 40 mg	1.78 (12.41)	30	✓	SimvaRex Lipex
	* Tab 80 mg	3.88 (14.39)	30		Lipex
47	SIMVASTATIN (↑ subsidy)– See prescribing guidelines on page 45 * Tab 80 mg	3.88	30	✓	SimvaRex
55	FUROSEMIDE (↓ subsidy and price) * Tab 40 mg - Up to 30 tab available on a PSO.....	10.75	1,000	✓	Diurin 40
59	CICLOPIROXOLAMINE (↓ subsidy and price) a) Only on a prescription b) not in combination Nail soln 8%	19.85	3.5 ml OP	✓	Batrafen

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details Schedule page ref	Subsidy (Mnfr's price) \$	Per	Brand or Generic Mnfr ✓ fully subsidised
---	---------------------------------	-----	--

Changes to Subsidy and Manufacturer's Price - effective 1 May 2009 (continued)

85	ERYTHROMYCIN ETHYL SUCCINATE (↓ subsidy and price) Tab 400 mg - Up to 30 tab available on a PSO	16.95	100	✓E-Mycin
86	AMOXYCILLIN CLAVULANATE (↓ subsidy) Tab amoxicillin 500 mg with potassium clavulanate 125 mg - Up to 30 tab available on a PSO.....	5.02 (6.40)	20	Augmentin
88	HYDROXYCHLOROQUINE SULPHATE (↓ subsidy and price) * Tab 200 mg	22.50	100	✓Plaquenil
99	IBUPROFEN (↓ subsidy) * Tab 200 mg	1.60 (1.78)	100	I-Profen
108	METHADONE HYDROCHLORIDE (↓ subsidy and price) a) Only on a controlled drug form b) No patient co-payment payable c) Extemporaneously compounded methadone will only be reimbursed at the rate of the cheapest form available (methadone powder, not methadone tablets) d) For methadone hydrochloride oral liquid refer, page 162 ‡ Oral liq 2 mg per ml..... ‡ Oral liq 5 mg per ml..... ‡ Oral liq 10 mg per ml.....	5.95 5.55 8.95	200 ml 200 ml 200 ml	✓Biodone ✓Biodone Forte ✓Biodone Extra Forte
117	ENTACAPONE (↓ subsidy and price) ▲ Tab 200 mg	116.00	100	✓Comtan
154	LEVOCABASTINE (↓ price) Eye drops 0.5 mg per ml	8.71 (10.34)	4 ml OP	Livostin

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ **fully subsidised**

Changes to Description

Effective 1 May 2009

86	BENZATHINE BENZYL PENICILLIN Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO...200.00	10	✓ Bicillin LA
----	---	----	----------------------

Changes to Sole Subsidised Supply

Effective 1 June 2009

For the list of new Sole Subsidised Supply products effective 1 June 2009 refer to the bold entries in the cumulative Sole Subsidised Supply table pages 9-18.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Delisted Items

Effective 1 May 2009

49	DOXAZOSIN MESYLATE * Tab 2 mg Note – the 500 tablet pack listed 1 November 2008	4.81	100	✓ Apo-Doxazosin
77	OESTRADIOL VALERATE – See prescribing guideline * Tab 2 mg	4.12	28	✓ Progynova
107	PARACETAMOL * Tab 500 mg – Up to 30 tab available on a PSO	1.38 (14.67)	150	Panadol
107	PARACETAMOL * Tab 500 mg	137.81 (1,467.00)	15,000	Panadol

continued...

Patients pay a manufacturer's surcharge when
the Manufacturer's Price is greater than the Subsidy

S29 Unapproved medicine supplied under Section 29
‡ safety cap reimbursed **Sole Subsidised Supply**

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be Delisted

Effective 1 July 2009

63	ETHINYLOESTRADIOL WITH LEVONORGESTREL * Tab 9.45	84	✓ Triquilar ED
64	OESTRADIOL WITH LEVONORGESTREL * Tab 2 mg with 75 µg levonorgestrel and tab 2mg Oestradiol (48) 16.20	84	✓ Nuvelle

Effective 1 August 2009

84	MEBENDAZOLE Tab 100 mg 2.53 (7.43)	4	Vermox
----	--	---	--------

Effective 1 October 2009

49	TERAZOSIN HYDROCHLORIDE * Tab 2 mg 1.48 (4.66)	28	Hytrin
	* Tab 5 mg 1.91 (5.60)	28	Hytrin
142	AZATHIOPRINE – Retail pharmacy-Specialist * Tab 50 mg 25.00	100	✓ Thioprine

Effective 1 November 2009

172	PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3] Liquid (strawberry) 1.60 200 ml OP ✓ Fortini Liquid (vanilla) 1.60 200 ml OP ✓ Fortini		
172	PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA0896 above – Hospital pharmacy [HP3] Liquid (chocolate) 1.60 200 ml OP ✓ Fortini Multifibre Liquid (strawberry) 1.60 200 ml OP ✓ Fortini Multifibre Liquid (vanilla) 1.60 200 ml OP ✓ Fortini Multifibre		

Effective 1 December 2009

25	CALCIUM CARBONATE WITH AMINOACETIC ACID * Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of \$38.73 per 1000 with Endorsement 30.00 (38.73)	1,000	Titralac
63	OIL IN WATER EMULSION * Crm 2.80	500g	✓ Lemnis Fatty Cream

▲ Three months supply may be dispensed at one time if endorsed “certified exemption” by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Check your Schedule for full details
Schedule page ref

Subsidy
(Mnfr's price)
\$ Per

Brand or
Generic Mnfr
✓ fully subsidised

Items to be delisted - effective 1 December 2009 (continued)

64	WOOL FAT WITH MINERAL OIL – Only on a prescription * Lotn hydrous 3% with mineral oil.....	5.60 (9.54)	1,000 ml		Hydroderm Lotion
92	EFAVIRENZ – Special Authority see SA0779 on the preceding page – Hospital pharmacy [HP1] Tab 50 mg	158.33	30	✓	Stocrin
	Tab 200 mg	474.99	90	✓	Stocrin
100	INDOMETHACIN * Cap 25 mg	5.90	100	✓	Rheumacin
110	NORTRIPTYLINE HYDROCHLORIDE Tab 25 mg	20.06	250	✓	Norpress
176	ENTERAL FEED WITH FIBRE 1KCAL/ML – Special Authority see SA0702 on page 174 – Hospital pharmacy [HP3] Liquid.....	1.24 5.29	250 ml OP 1,000 ml OP	✓ ✓	Fibresource Fibresource RTH
156	PILOCARPINE * Eye drops 0.5%	3.19	15 ml OP	✓	Pilopt

Section H changes to Part I

Effective 1 May 2009

14 Discretionary Community Supply Pharmaceuticals

- 8.1 Discretionary Community Supply Pharmaceuticals are deemed to include every medicine, therapeutic medical device, or related product or related thing listed in Section H Part IV of the Schedule.
- 8.2 PHARMAC may, in its discretion, list any pharmaceutical that is not a Community Pharmaceutical as a Discretionary Community Supply Pharmaceutical, including a pharmaceutical that PHARMAC is made aware of by HPAC, the Exceptional Circumstances Panel, a DHB Hospital or relevant hospital personnel.
- 8.3 A DHB Hospital may use its discretion to purchase Discretionary Community Supply Pharmaceuticals for use in the community, provided that, if the patient being treated with a Discretionary Community Supply Pharmaceutical usually resides in a district other than that within the jurisdiction of the DHB initiating the treatment, then the DHB initiating the treatment must either agree to fund any on-going treatment required once the patient has returned to his/her usual DHB, or obtain written consent from the DHB or DHBs in which the patient will reside following the commencement of treatment.
- 8.4 The funding of a Discretionary Community Supply Pharmaceutical for use in the community will be sourced from the relevant DHBs own budget. For the avoidance of doubt, the Discretionary Community Supply Pharmaceutical is not a Community Pharmaceutical and funding is not available for Discretionary Community Supply Pharmaceuticals from the Pharmaceutical Budget.
- 8.5 Subject to rule 8.6, DHB Hospitals must not fund for use in the community, any pharmaceuticals that are not Discretionary Community Supply Pharmaceuticals unless they have been approved under Hospital Exceptional Circumstances.
- 8.6 DHB Hospitals may fund from their own budgets, any Pharmaceutical that is listed in Sections A-G of the Pharmaceutical Schedule without Hospital Exceptional Circumstances (HEC) approval provided that:
- ~~(a) the condition for which that Pharmaceutical is supplied is consistent with any restrictions applying to that Pharmaceutical in Section A-G of the Pharmaceutical Schedule; and~~
 - (ba) (i) up to 5 days treatment, or one original pack, (where inappropriate to provide less); or**
 - (ii) more than 5 days treatment, provided that the relevant DHB Hospital has a dispensing for discharge policy and the quantity supplied is in accordance with that policy; and**
 - (b) the Pharmaceutical is supplied consistent with any restrictions applying to that Pharmaceutical in Section A-G of the Pharmaceutical Schedule.**

Note dispensing for discharge as described in rule 8.6 is at the discretion of individual DHBs.

▲ Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

* Three months or six months, as applicable, dispensed all-at-once

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II

Effective 1 June 2009

ACETYLCYSTEINE (new listing)

Inj 200 mg per ml, 10 ml	Martindale Acetylcysteine	219.75	10			
--------------------------------	------------------------------	--------	----	--	--	--

BENZATHINE BENZYL PENICILLIN († price)

Inj 1.2 mega u per 2.3 ml.....	Bicillin LA	315.00	10			
--------------------------------	-------------	--------	----	--	--	--

DILTIAZEM HYDROCHLORIDE (↓ price)

Cap long-acting 120 mg	Cardizem CD	4.34	30	5%	Jun-09	(B)
Cap long-acting 180 mg	Cardizem CD	6.50	30	5%	Jun-09	Dilzem LA
Cap long-acting 240 mg	Cardizem CD	8.67	30	5%	Jun-09	Dilzem LA

ERYTHROPOIETIN BETA (delisting)

Inj 1,000 iu prefilled syringe.....	Recormon	48.68	6			
Inj 2,000 iu prefilled syringe.....	Recormon	120.18	6			
Inj 3,000 iu prefilled syringe.....	Recormon	166.87	6			
Inj 4,000 iu prefilled syringe.....	Recormon	193.13	6			
Inj 5,000 iu prefilled syringe.....	Recormon	243.26	6			
Inj 6,000 iu prefilled syringe.....	Recormon	291.92	6			
Inj 10,000 iu prefilled syringe.....	Recormon	760.20	6			

HYDROCORTISONE (new listing and HSS)

Powder	ABM	33.00	25 g	1%	Aug-09	Apo-Hydrocortisone m-Hydrocortisone Pharmacia
--------------	------------	-------	------	----	--------	---

METOPROLOL SUCCINATE (new listing)

Tab long-acting 23.75 mg	Metoprolol-AFT CR	2.73	30			
Tab long-acting 47.5 mg.....	Metoprolol-AFT CR	3.41	30			
Tab long-acting 95 mg.....	Metoprolol-AFT CR	5.88	30			
Tab long-acting 190 mg	Metoprolol-AFT CR	10.63	30			

ROPINIROLE HYDROCHLORIDE (delisting)

Tab 0.25 mg.....	Requip	31.50	210			
Tab 0.25 mg x 42, 0.5 mg x 42, and 1 mg x 21	Requip Starter Pack	35.70	105-OP			
Tab 0.25 mg x 42, 1 mg x 42, and 2 mg x 63	Requip Follow-on Pack	122.11	147-OP			
Tab 1 mg	Requip	67.20				
Tab 2 mg.....	Requip	101.21				
Tab 5 mg.....	Requip	150.00				

Products with Hospital Supply Status (HSS) are in **bold**.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II - effective 1 May 2009

ACARBOSE (new listing and HSS)						
Tab 50 mg.....	Glucobay	16.50	90	1%	Jul-09	(B)
Tab 100 mg.....	Glucobay	26.70	90	1%	Jul-09	(B)
CO-TRIMOXAZOLE (new listing)						
Oral liq 240 mg per 5 ml.....	Deprim	2.15	100 ml			
ENTACAPONE (new listing and HSS)						
Tab 200 mg.....	Comtan	116.00	100	1%	Jul-09	(B)
ERYTHROMYCIN ETHYL SUCCINATE (↓ price and HSS)						
Tab 400 mg.....	E-Myacin	16.95	100	1%	Jul-09	(B)
FRUSEMIDE FUROSEMIDE (Change in chemical name, ↓ price and HSS)						
Tab 40 mg.....	Diurin 40	10.75	1,000	1%	Jul-09	Apo-Frusemide Frusehexal Frusid
HYDROXYCHLOROQUINE SULPHATE (↓ price and HSS)						
Tab 200 mg.....	Plaquenil	22.50	100	1%	Jul-09	(B)
LIGNOCAINE WITH PRILOCAINE (delisting)						
Patch 2.5% with prilocaine 2.5%.....	EMLA	10.40	2			
METHADONE HYDROCHLORIDE (↓ price and HSS)						
Oral liq 2 mg per ml.....	Biodone	5.95	200 ml	1%	Jul-09	(B)
Oral liq 5 mg per ml.....	Biodone Forte	5.55	200 ml	1%	Jul-09	(B)
Oral liq 10 mg per ml.....	Biodone Extra Forte	8.95	200 ml	1%	Jul-09	(B)
OMEPRAZOLE (addition of HSS)						
Cap 10 mg.....	Dr Reddy's Omeprazole	2.14	30	1%	May-09	Losec Omezol
Cap 20 mg.....	Dr Reddy's Omeprazole	3.05	30	1%	May-09	Losec Omezol
Cap 40 mg.....	Dr Reddy's Omeprazole	3.59	30	1%	May-09	Losec Omezol
OMEPRAZOLE (delisting)						
Inf 40 mg.....	Losec IV	38.65	5			
SPECIAL FOOD SUPPLEMENT (new listing)						
Liquid, 237 ml.....	Impact Advanced Recovery Vanilla and Chocolate		3.50		237 ml	
SPECIAL FOOD SUPPLEMENT (delisting)						
Powder, sachet 74 g.....	Oral Impact	17.50	5			

Effective 1 April 2009

AMIKACIN SULPHATE (delisting date)						
Inj 250 mg per ml, 2 ml.....	Amikin	15.00	1	1%	Sept-06	(B)
Note- This product will be delisted 1 July 2009						

Products with Hospital Supply Status (HSS) are in **bold**.

(B) – Subject only to part (b) of the definition of “DV Pharmaceutical”

Contracted Pharmaceutical Description	Brand	Price (\$) (ex man. excl. GST)	Per	DV Limit	DV Limit applies from	DV Pharmaceutical
---------------------------------------	-------	--------------------------------	-----	----------	-----------------------	-------------------

Section H changes to Part II - effective 1 April 2009 (continued)

APOMORPHINE HYDROCHLORIDE (new listing)

Inj 10 mg per ml, 2 mlApomine 50.43 5

Note – The Mayne brand of Apomorphine hydrochloride inj 10 mg per ml, 1 ml will be delisted from 1 October 2009.

ATOMOXETINE HYDROCHLORIDE (new listing)

Cap 10 mgStrattera 107.03 28
 Cap 18 mgStrattera 107.03 28
 Cap 25 mgStrattera 107.03 28
 Cap 40 mgStrattera 107.03 28
 Cap 60 mgStrattera 107.03 28
 Cap 80 mgStrattera 139.11 28
 Cap 100 mgStrattera 139.11 28

CLOZAPINE (new listing)

Tab 25 mg.....Clozaril 26.74 100
 Tab 100 mgClozaril 69.30 100

DANAZOL (new listing)

Cap 100 mgAzol 56.66 100

Note - D Zol brand of Danazol cap 100 mg 30 pack size to be delisted 1 October 2009

DIAZEPAM († price)

Rectal tubes 5 mgStesolid 25.05 5
 Rectal tubes 10 mgStesolid 30.50 5

GEMCITABINE HYDROCHLORIDE (new listing and HSS)

Inj 200 mg.....**Gemcitabine Ebewe**49.00 1 1% Jun-09 Gemzar
 Inj 1 g.....**Gemcitabine Ebewe**245.00 1 1% Jun-09 Hospira
 Gemzar
 Hospira

OMEPRAZOLE (addition of HSS)

Inj 40 mg.....**Dr Reddy's Omeprazole** 38.20 5 1% May-09 Losec
 Inf 40 mg**Dr Reddy's Omeprazole** 38.65 5 1% May-09 Losec IV

PARACETAMOL († price)

Suppos 125 mg.....Panadol 7.49 20
 Suppos 250 mg.....Panadol 14.40 20

ROPINIROLE (new listing and HSS)

Tab 0.25 mg**Ropin** 7.90 84 1% June-09 Requip
 Tab 1 mg**Ropin** 40.32 84 1% June-09 Requip
 Tab 2 mg**Ropin** 60.72 84 1% June-09 Requip
 Tab 5 mg**Ropin** 90.00 84 1% June-09 Requip

Note – Requip tab 0.25mg, 1 mg, 2 mg and 5mg and Requip Starter pack and Follow-on pack will all be delisted 1 September 2009

VERAPAMIL (delisting)

Tab 40 mgVerpamil 4.75 100

Section H changes to Part IV

Effective 1 June 2009

HYDRALAZINE

Tab 25 mg **S29**

For patients with congestive heart failure:

- (1) who have not responded to treatment with ACE inhibitors and/or ARBs; or
- (2) in whom treatment with ACE inhibitors and/or ARBs is not tolerated due to renal impairment

INDOMETHACIN

Cap 25 mg **S29**

For any indication approved by the hospital service

METOLAZONE **S29**

Tab 5 mg

For patients with congestive heart failure:

- (1) who have not responded to treatment with ACE inhibitors and/or ARBs; or
- (2) in whom treatment with ACE inhibitors and/or ARBs is not tolerated due to renal impairment

L-ORNITHINE L-ASPARTATE (LOLA) **S29**

Sach 5 mg

For patients with chronic hepatic encephalopathy who have not responded to treatment with lactulose

Effective 1 May 2009

INDOMETHACIN

Cap 50 mg **S29**

For any indication approved by the hospital service

SPECIAL FOOD SUPPLEMENT (delisting)

Powder, sachet 74 g ~~_____~~ Oral Impact

~~Three sachets per day for 5-7 days prior to major gastrointestinal or head or neck surgery~~

Index

Pharmaceuticals and brands

A	
Acarbose	23, 31
Acetylcysteine	19, 30
Amikacin sulphate	31
Amikin	31
Amoxicillin clavulanate	24
Apo-Doxazosin	26
Apomine	32
Apo-Terazosin	19
Apomorphine hydrochloride	32
Atomoxetine hydrochloride	32
Atorvastatin	19
Augmentin	24
Azathioprine	27
Azol	32
B	
Batrafen	21
Batrafen	23
Benzathine benzylpenicillin	22, 25, 30
Bicillin LA	22, 25, 30
Biodone	24, 31
Biodone Extra Forte	24, 31
Biodone Forte	24, 31
C	
Calcium carbonate with aminoacetic acid	23, 27
Calcium folinate	22
Calcium Folate Ebewe	22
Cardizem CD	22, 30
Ciclopirox olamine	21
Ciclopiroxolamine	21, 23
Clinistix	23
Clinitest	23
Clozapine	32
Clozaril	32
Co-trimoxazole	19, 31
Comtan	24, 31
Copper	23
D	
Daonil	19
Deprim	19, 31
Diltiazem hydrochloride	22, 30
Diurin 40	21
Doxazosin mesylate	26
Dr Reddy's Omeprazole	31, 32
Danazol	32
Diastix	23
Diazepam	32
Diurin 40	23, 31
Diurin 500	21
E	
Efavirenz	28
E-Mycin	24, 31
EMLA	31
Entacapone	24, 31
Enteral feed with fibre 1kcal/ml	28
Erythromycin ethyl succinate	24, 31
Erythropoietin beta	30
Ethinylestradiol with levonorgestrel	27
F	
Fibresource	28
Fibresource RTH	28
Fortini	27
Fortini Multifibre	27
Furosemide	21, 31
Furosemide	21, 23, 31
G	
Gemcitabine Ebewe	32
Gemcitabine hydrochloride	22, 32
Glibenclamide	19
Glucobay	23, 31
Glucose oxidase	23
H	
Hydralazine	33
Hydrocortisone	19, 30
Hydroderm Lotion	28
Hydroxychloroquine sulphate	24, 31
Hytrin	27
I	
Ibuprofen	24
Impact Advanced Recovery Vanilla and Chocolate	31
Indomethacin	33
I-Profen	24
Indomethacin	28
K	
Keto-Diastix	23
Ketostix	23
L	
Lasix	21
Lemnis Fatty Cream	27
Levocabastine	24
Lignocaine with prilocaine	31
Lipex	23
Lipitor	19
Livostin	24
L-ornithine l-aspartate (Iola)	33
Losec IV	31
M	
Mebendazole	27
Metolazone	33
Metoprolol-AFT CR	19, 30
Methadone hydrochloride	24, 31
Metoprolol succinate	19, 30
N	
Norpress	19, 28

Index

Pharmaceuticals and brands

Nortriptyline hydrochloride.....	19, 28
NutriniDrink.....	19
NutriniDrink Multifibre.....	20
Nuvelle.....	27
O	
Oestradiol valerate.....	26
Oestradiol with levonorgestrel.....	27
Oestrogens.....	22
Oestrogens with medroxyprogesterone.....	22
Oil in water emulsion.....	27
Omeprazole.....	31
Omeprazole (HSS).....	32
Oral Impact.....	31, 33
P	
Paclitaxel.....	19
Paclitaxel Ebewe.....	19
Paediatric oral feed 1.5kcal/ml.....	19, 27
Paediatric oral feed with fibre 1.5kcal/ml.....	20, 27
Pamidronate disodium.....	19
Pamisol.....	19
Panadol.....	26, 32
Paracetamol.....	26, 32
Pilocarpine.....	28
Pilopt.....	28
Plaquenil.....	24, 31
Premarin.....	22
Premia 2.5 Continuous.....	22
Premia 5 Continuous.....	22
Progynova.....	26
R	
Recormon.....	30
Requip.....	22, 30
Requip Follow-on Pack.....	22, 30
Requip Starter Pack.....	22, 30
Rheumacin.....	28
Ropin.....	32
Ropinirole.....	32
Ropinirole hydrochloride.....	22, 30
S	
SimvaRex.....	23
Simvastatin.....	23
Sodium nitroprusside.....	23
Special food supplement.....	31, 33
Stesolid.....	32
Stocrin.....	28
Strattera.....	32
T	
Terazosin hydrochloride.....	19, 27
Thioprine.....	27
Titralac.....	23, 27
Triquilar ED.....	27
V	
Verapamil.....	32
Vermox.....	27
Verpamil.....	32
W	
Wool fat with mineral oil.....	28

Pharmaceutical Management Agency

Level 9, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - www.pharmac.govt.nz

Freephone Information line (9am-5pm weekdays) 0800 66 00 50



PHARMAC is the Government agency responsible for deciding which medicines are subsidised for New Zealanders. It manages spending on pharmaceuticals for the District Health Boards, and ensures that a comprehensive list of medicines (the Pharmaceutical Schedule) is subsidised for New Zealanders, and that the list of medicines continues to grow to meet the needs of patients.